Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03058718
Other study ID # lwsrmyy
Secondary ID
Status Completed
Phase N/A
First received February 16, 2017
Last updated February 16, 2017
Start date January 1, 2014
Est. completion date February 1, 2017

Study information

Verified date February 2017
Source Qilu Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To explore effectiveness of procalcitonin-guided antibiotic therapy in acute exacerbations of bronchiectasis, and to explore the clinical value of procalcitonin in bronchiectasis.


Recruitment information / eligibility

Status Completed
Enrollment 210
Est. completion date February 1, 2017
Est. primary completion date July 1, 2016
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Bronchiectasis was diagnosed by high-resolution computed tomography based on the criteria published by McShane PJ et al.

2. Acute exacerbations of bronchiectasis.

3. Aged >= 18 years.

4. Procalcitonin been detected after admission.

Exclusion Criteria:

1. Associated with chronic obstructive pulmonary disease.

2. Associated with asthma.

3. Traction bronchiectasis caused by pulmonary fibrosis.

4. Rule out other possible cause procalcitonin increased diseases such as cancer, connective tissue disease, active tuberculosis, chronic liver disease and respiratory system than the bacterial infection.

5. Clinical data were incomplete.

6. Can not follow up with the person.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Procalcitonin
The application of antimicrobial agents is determined by PCT results.
Clinical Experience
The application of antimicrobial agents is determined by clinical experience of doctors.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Qilu Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Antimicrobial prescription rate 14 days
Primary Number of days of antimicrobial application 14 days
Primary The number of days in hospital 14 days
Secondary Effective rate of clinical treatment 14 days
Secondary Quality of life score 6 months
Secondary Adverse reaction rate 14 days
Secondary Bacterial resistance rate 14 days
Secondary The incidence of complications 14 days
Secondary fungal infection rate 14 days
Secondary mortality rate 14 days
Secondary The proportion of patients with at least once acute exacerbation in 6 months 6 months
See also
  Status Clinical Trial Phase
Completed NCT05034900 - Does Addition of Oscillatory Positive Expiratory Pressure (OPEP) Device to a Chest Physiotherapy Program Provide Further Health Benefits in Children With Bronchiectasis? N/A
Recruiting NCT04101448 - Prevalence of Bronchiectasis in COPD Patients
Withdrawn NCT03376204 - Pain Mechanisms in Patients With Bronchiectasis
Completed NCT02550821 - Comparison of Physical Activity Level Between Patients With Bronchiectasis and Healthy Subjects
Completed NCT02656992 - Effects of High Intensity Inspiratory Muscle Training on Exercise Capacity in Patients With Bronchiectasis N/A
Completed NCT02282202 - Evaluation of Oscillatory Positive Expiratory Pressure (oPEP) in Bronchiectasis and COPD N/A
Completed NCT02048397 - Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis N/A
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Recruiting NCT01761214 - Bacteriology and Inflammation in Bronchiectasis N/A
Recruiting NCT02527486 - Seoul National University Airway Registry N/A
Completed NCT01578681 - ELTGOL and Bronchiectasis. Respiratory Therapy N/A
Completed NCT01854788 - 3 Airway Clearance Techniques in Non Cystic Fibrosis Bronchiectasis N/A
Completed NCT00769119 - A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis Phase 2
Terminated NCT00524095 - Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis Phase 2
Completed NCT01117493 - Expert Patient Self-management Programme Versus Usual Care in Bronchiectasis N/A
Recruiting NCT00129350 - Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation Phase 1
Completed NCT00656721 - Respiratory Mechanics Effects of Flutter Valve in Bronchiectasis Patients N/A
Completed NCT04081740 - Biological Determinants of Sputum Rheology in Chronic Airway Diseases
Enrolling by invitation NCT02546297 - Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis Phase 4
Completed NCT03628456 - Effect of HFCWO Vests on Spirometry Measurements N/A